25 results
10-K/A
2022 FY
STSA
Satsuma Pharmaceuticals Inc
28 Apr 23
Annual report (amended)
4:08pm
commitment to the longer-term strategies and operating results of the Company. We further believe this compensation mix rewards each executive, including
8-K
EX-2.2
STSA
Satsuma Pharmaceuticals Inc
17 Apr 23
SNBL to Acquire Satsuma Pharmaceuticals
6:34am
of such security or any interest in such security to any Person other than Parent or Purchaser; (ii) enters into an agreement or commitment contemplating
8-K
EX-2.1
STSA
Satsuma Pharmaceuticals Inc
17 Apr 23
SNBL to Acquire Satsuma Pharmaceuticals
6:34am
the Exchange Act with respect to such reports.
(e) Neither the Company nor any Company Subsidiary is a party to, or has any commitment to become a party … by applicable Law, existing written commitment or as required by the terms of any Company Plan set forth in Section 4.10 of the Company Disclosure
8-K
EX-99.1
bi7dyrfijh4lee686eh
25 Mar 21
Satsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
5:02pm
8-K
EX-10.1
bo5sq
1 Mar 21
Satsuma Pharmaceuticals Announces Updated STS101 Development Plan
12:00am
8-K
EX-99.1
lt9i4eu fnw6d3er
12 May 20
Satsuma Pharmaceuticals Reports First Quarter 2020 Financial and Business Results
4:30pm
DEF 14A
z8yayjn81p5y03cv2
24 Apr 20
Definitive proxy
4:14pm
10-K
4nx4pu0bl
10 Mar 20
Annual report
4:20pm
8-K
EX-3.2
08saep
17 Sep 19
Satsuma Pharmaceuticals, Inc. Announces Closing of Initial Public Offering
4:11pm
424B4
lcf lb7vt
13 Sep 19
Prospectus supplement with pricing info
5:08pm
S-1/A
mdiel8b pctqzj25e
3 Sep 19
IPO registration (amended)
6:12am
S-1/A
EX-3.2
2vc0opah
3 Sep 19
IPO registration (amended)
6:12am
S-1
EX-3.5
htnb01ew89nfnisjrd4q
16 Aug 19
IPO registration
5:15pm
S-1
EX-10.3
nda3n
16 Aug 19
IPO registration
5:15pm
S-1
1m31qfd3j2tyoz8
16 Aug 19
IPO registration
5:15pm
S-1
EX-3.1
58w0lw0janvzm
16 Aug 19
IPO registration
5:15pm